7513 CofD-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Organoheterocyclic compounds | 2 | 0.6 | 3.29× | not tested | |
| Nucleosides, nucleotides, and analogues | 3 | 1.1 | 2.75× | not tested | |
| Homogeneous non-metal compounds | 1 | 0.9 | 1.18× | not tested | |
| Homogeneous metal compounds | 1 | 1.9 | 0.52× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04315 | GDP | Guanosine-5'-Diphosphate | 8 |
| DB14128 | NAD | Nadide | 4 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| FO1 | 1-deoxy-1-(8-hydroxy-2,4-dioxo-3,4-dihydropyrimido[4,5-b]quinolin-10(2H)-yl)-D-ribitol | 10 |
| CAmetal | CALCIUM ION | 9 |
| GDP | GUANOSINE-5'-DIPHOSPHATE | 8 |
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 4 |
| CL | CHLORIDE ION | 1 |
| QMD | 2-[oxidanyl-[(2~{R},3~{S},4~{S})-2,3,4-tris(oxidanyl)-5-[2,4,8-tris(oxidanylidene)-1,9-dihydropyrimido[4,5-b]quinolin-10-yl]pentoxy]phosphoryl]oxyprop-2-enoic acid | 1 |